BioDetego
Philadelphia, Pennsylvania, United States
About BioDetego
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $50.0K
- Funding stage: Seed
- Last round: Seed (May 2014)
- Website: biodetego.com
Industries & Categories
Biotechnology, Clinical Trials, Health Diagnostics, Oncology
Canonical: https://fsome.com/organization/biodetego-2557688 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.